Skip to main content
Premium Trial:

Request an Annual Quote

New York State Grants Clinical Lab Permit to Empire Genomics

NEW YORK (GenomeWeb) – Cancer diagnostics company Empire Genomics announced today that it has received approval from New York State to offer molecular and cellular tumor marker testing through the state's Clinical Laboratory Evaluation Program (CLEP).

The company plans to offer genetic testing and molecular diagnostics to help physicians make treatment decisions for cancer patients. The CLEP program evaluates a clinical lab's ability to accurately and reliably deliver test results.

"The addition of molecular testing solidifies our test menu, allowing us to offer a more complete range of testing needed for personalized diagnostics and therapeutics," said COO John Rushton in a statement.

In December, the firm reported receiving CE Marking for several of its products including fluorescent in situ hybridization probes and karyotyping media.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.